XML 36 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
Segment Information (Tables)
 6 Months Ended
Dec. 31, 2014
Segment Reporting [Abstract]  
Revenue by Reportable Segment
The following tables present revenue for each reportable segment and Corporate:
 
Three Months Ended December 31
(in millions)
2014
 
2013
Pharmaceutical
$
22,627

 
$
19,443

Medical
2,914

 
2,799

Total segment revenue
25,541

 
22,242

Corporate (1)
(4
)
 
(2
)
Total revenue
$
25,537

 
$
22,240


 
Six Months Ended December 31
(in millions)
2014
 
2013
Pharmaceutical (2)
$
43,836


$
41,256

Medical
5,766


5,511

Total segment revenue
49,602


46,767

Corporate (1)
5


(4
)
Total revenue
$
49,607


$
46,763


(1)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
(2)
Our pharmaceutical distribution contract with Walgreen Co. expired on August 31, 2013.
 [1]
Segment Profit by Reportable Segment
The following tables present segment profit by reportable segment and Corporate:
 
Three Months Ended December 31
(in millions)
2014
 
2013
Pharmaceutical
$
542

 
$
482

Medical
115

 
131

Total segment profit
657

 
613

Corporate
(111
)
 
(94
)
Total operating earnings
$
546

 
$
519


 
Six Months Ended December 31
(in millions)
2014
 
2013
Pharmaceutical
$
992


$
916

Medical
229


238

Total segment profit
1,221


1,154

Corporate
(209
)

(164
)
Total operating earnings
$
1,012


$
990

 [1]
[1] Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.